NasdaqGS - Delayed Quote USD

AbCellera Biologics Inc. (ABCL)

3.7600 +0.1300 (+3.58%)
At close: April 26 at 4:00 PM EDT
3.7200 -0.04 (-1.06%)
After hours: April 26 at 6:57 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
38,025.0000
38,025.0000
485,424.0000
375,203.0000
233,155.0000
Cost of Revenue
--
--
66,436.0000
45,516.0000
27,143.0000
Gross Profit
38,025.0000
38,025.0000
418,988.0000
329,687.0000
206,012.0000
Operating Expense
261,077.0000
261,077.0000
191,923.0000
107,788.0000
41,661.0000
Operating Income
-223,052.0000
-223,052.0000
227,065.0000
221,899.0000
164,351.0000
Net Non Operating Interest Income Expense
42,247.0000
42,247.0000
16,079.0000
3,330.0000
-6,218.0000
Other Income Expense
6,776.0000
6,776.0000
-4,045.0000
-6,080.0000
-300.0000
Pretax Income
-174,029.0000
-174,029.0000
239,099.0000
219,149.0000
157,833.0000
Tax Provision
-27,631.0000
-27,631.0000
80,580.0000
65,685.0000
38,915.0000
Net Income Common Stockholders
-146,398.0000
-146,398.0000
158,519.0000
153,464.0000
85,101.0000
Diluted NI Available to Com Stockholders
-146,398.0000
-146,398.0000
158,519.0000
153,464.0000
85,101.0000
Basic EPS
-0.51
--
0.56
0.56
0.53
Diluted EPS
-0.51
--
0.50
0.48
0.45
Basic Average Shares
289,166.4860
--
285,056.6060
275,763.7450
159,195.0230
Diluted Average Shares
289,166.4860
--
314,827.2550
318,294.2360
263,129.7650
Total Operating Income as Reported
-237,207.0000
-237,207.0000
216,511.0000
204,413.0000
156,031.0000
Total Expenses
261,077.0000
261,077.0000
258,359.0000
153,304.0000
68,804.0000
Net Income from Continuing & Discontinued Operation
-146,398.0000
-146,398.0000
158,519.0000
153,464.0000
118,918.0000
Normalized Income
-146,398.0000
-146,398.0000
158,519.0000
153,464.0000
119,144.0326
Interest Income
42,247.0000
42,247.0000
16,079.0000
3,330.0000
293.0000
Interest Expense
--
--
4,045.0000
5,225.0000
6,511.0000
Net Interest Income
42,247.0000
42,247.0000
16,079.0000
3,330.0000
-6,218.0000
EBIT
-223,052.0000
-223,052.0000
227,065.0000
221,899.0000
164,344.0000
EBITDA
-192,158.0000
-192,158.0000
260,167.0000
239,149.0000
169,615.0000
Reconciled Cost of Revenue
--
--
61,177.0000
42,717.0000
26,708.0000
Reconciled Depreciation
30,894.0000
30,894.0000
33,102.0000
17,250.0000
5,271.0000
Net Income from Continuing Operation Net Minority Interest
-146,398.0000
-146,398.0000
158,519.0000
153,464.0000
118,918.0000
Total Unusual Items Excluding Goodwill
--
--
--
-855.0000
-300.0000
Total Unusual Items
--
--
--
-855.0000
-300.0000
Normalized EBITDA
-192,158.0000
-192,158.0000
260,167.0000
239,149.0000
169,915.0000
Tax Rate for Calcs
0.0002
0.0002
0.0003
0.0003
0.0002
Tax Effect of Unusual Items
--
--
--
--
-73.9674
12/31/2020 - 12/11/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

NTLA Intellia Therapeutics, Inc.
20.76
+3.70%
 
DNA Ginkgo Bioworks Holdings, Inc.
0.8601
+10.60%
 
BEAM Beam Therapeutics Inc.
21.38
-1.02%
 
RXRX Recursion Pharmaceuticals, Inc.
8.12
+3.57%
 
ADPT Adaptive Biotechnologies Corporation
2.6000
-0.38%
 
CRBU Caribou Biosciences, Inc.
3.7100
-1.33%
 
EDIT Editas Medicine, Inc.
5.32
+1.92%
 
CRSP CRISPR Therapeutics AG
53.91
+0.34%
 
EXAI Exscientia plc
4.0300
+1.00%
 
PRME Prime Medicine, Inc.
4.4250
+2.91%